Converging GLP-1 / tirzepatide / semaglutide / retatrutide postmarket safety
Key Questions
What is the FDA saying about compounded versus brand-name GLP-1 drugs?
The FDA continues to issue warnings distinguishing compounded versions from approved brands due to safety and quality concerns. It has also named a peptide compounding committee amid rising safety issues.
How many GLP-1 overdose cases are occurring each month?
Overdoses are rising at a rate of 95 cases per month, representing a 265% increase. This trend is linked to both compounded products and dosing errors.
What concerns exist about RFK Jr.'s changes to FDA advisory panels on peptides?
FDA scientists warn against expanded peptide access as RFK Jr. reshapes panels with industry-tied members, raising regulatory capture risks. The new committee has also drawn safety concerns.
Are microdosing practices for GLP-1s considered safe?
Forbes and other sources warn that microdosing GLP-1s involves unapproved dosing not backed by clinical evidence. Such practices carry risks of improper use and adverse effects.
What patient safety resources are available for compounded GLP-1s?
New guides include Q&A documents, red flag checklists, and a PDF summarizing FDA warnings on compounded semaglutide. These help users verify pharmacy labels and spot risks.
What side effects are clinicians highlighting with GLP-1 weight-loss drugs?
Ongoing issues include muscle loss, reduced bone density, and oral side effects, with some framing the drugs as potentially causing nutritional depletion. One article calls them a possible 'disaster in the making' if weight loss is confused with healthy fat loss.
What is the status of retatrutide development?
Retatrutide remains in phase 3 trials while postmarket monitoring continues for related GLP-1 drugs. Safety signals around liver benefits and black-market risks are also being tracked.
How are telehealth providers being affected by GLP-1 enforcement?
Ongoing enforcement actions target telehealth prescribing of compounded GLP-1s amid broader regulatory scrutiny. This is part of efforts to curb unsafe compounded products.
FDA continues warnings on compounded vs brand; overdoses rising (95 cases/month, 265% increase). New: Gallup poll shows 15% of Americans have tried weight-loss drugs, 11% currently using, 19% use compounded versions. FDA scientists warn against expanded peptide access as RFK Jr. reshapes advisory panel with industry-tied members. FDA names peptide compounding committee. Ongoing: muscle loss, bone density, oral side effects, liver benefits, retatrutide phase 3, black market risks, telehealth enforcement. New: Patient safety guides for compounded GLP-1s (Q&A, red flags/green lights) being published. New: Compounded semaglutide safety PDF summarizing FDA warnings. New: Microdosing GLP-1s trending – Forbes article warns against unapproved dosing practices. New: Article warns GLP-1s may be 'disaster in the making' – clinician cautions about muscle loss and nutritional depletion. New: Practical guide on reading compounding pharmacy labels for GLP-1s.